Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MCS2104
- Development stage
- Preclinical
- Lead developer
- PharmaCept
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Hydrogel Systems → Drug Delivery Systems
01
Overview
**MCS2104** is a conceptual-stage Magle Pharmacept regenerative-medicine candidate in the GelSpheres program. It is described as a new composition for dental bone tissue engineering that incorporates an mRNA molecule intended to induce and facilitate tissue repair and regeneration by accelerating normal physiological repair processes. The specific mRNA sequence, molecular target, delivery composition, route of administration, and clinical indication have not been publicly disclosed. ([maglepharmacept.com](https://maglepharmacept.com/our-pipeline/))
Beyond the preview
Go deeper on MCS2104.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MCS2104.